Paclitaxel Albumin-Stabilized Nanoparticle Formulation After Cisplatin-Based Chemotherapy and Surgery in Treating Patients With High-Risk Bladder Cancer

PRIMARY OBJECTIVES:

I. To evaluate the 6-month progression-free survival (PFS) rate in patients with high risk
urothelial carcinoma treated with cisplatin-based neoadjuvant chemotherapy followed by
curative intent cystectomy receiving maintenance therapy with paclitaxel albumin-stabilized
nanoparticle formulation (nab-paclitaxel).

SECONDARY OBJECTIVES:

I. To evaluate overall survival (OS), time to progression and duration of response in
patients treated with cisplatin-based neoadjuvant chemotherapy followed by curative intent
cystectomy receiving maintenance therapy with nab-paclitaxel.

II. To evaluate the adverse events associated with use of single agent nab-paclitaxel
(Abraxane®) in patients with high risk urothelial carcinoma receiving maintenance therapy
III. To evaluate Health Related Quality of life (HRQoL) as assessed by the European
Organization for Research and Treatment of Care (EORTC) QLQ-C30.

TERTIARY OBJECTIVES:

I. To determine the presence of circulating tumor cells (CTC) in high risk patients with
urothelial carcinoma prior to initiation of maintenance therapy (baseline) and after
nab-paclitaxel exposure (at cycles 2, 4).

OUTLINE:

Patients receive paclitaxel albumin-stabilized nanoparticle formulation intravenously (IV)
over 30 minutes on days 1, 8, and 15. Treatment repeats every 28 days for up to 4 courses in
the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up every 3 months for 2 years.

Inclusion Criteria:

- Histological confirmation of urothelial carcinoma and high risk residual disease
after neoadjuvant chemotherapy (NAC) and cystectomy as defined by post-operative
pathological pT4 or N1-3 disease, or progressive disease during NAC (NAC include
methotrexate, vinblastin, doxorubicin and cisplatin [MVAC], dose dense MVAC,
gemcitabine cisplatin, or gemcitabine carboplatin); minor histologic variants (< 50%)
are acceptable if urothelial carcinoma is predominant variant

- Post-operative computed tomography (CT) scan of the chest, abdomen, and pelvis =< 30
days prior to registration demonstrating no evidence of residual or recurrent
malignancy

- Life expectancy >= 12 weeks

- Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1 or 2

- Absolute neutrophil count (ANC) >= 1500/mm^3

- Platelet count >= 100,000/mm^3

- Hemoglobin >= 9.0 g/dL

- Total bilirubin =< 1.5 mg/dL

- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN

- Alkaline phosphatase =< 2.5 x upper limit of normal (ULN)

- Creatinine =< 1.5 mg/dL or creatinine clearance >= 40mL/mon (using Cockcroft-Gault
formula)

- Females of child-bearing potential, defined as a sexually mature woman who (1) has
not undergone hysterectomy or bilateral oophorectomy or (2) has not been naturally
postmenopausal for at least 24 consecutive months must:

- Either commit to true abstinence from heterosexual contact (which must be
reviewed on a monthly basis), or agree to use, and be able to comply with,
effective contraception without interruption, 28 days prior to starting
intraperitoneal (IP) therapy (including dose interruptions), and while on study
medication or for a longer period if required by local regulations following the
last dose of IP

- Negative serum pregnancy test done =< 7 days prior to registration and agree to
ongoing pregnancy testing during the course of the study, and after the end of
study therapy; this applies even if the subject practices true abstinence from
heterosexual contact

- Male subjects must practice true abstinence or agree to use a condom during sexual
contact with a pregnant female or a female of childbearing potential while
participating in the study, during those interruptions and for 6 months following IP
discontinuation, even if he has undergone a successful vasectomy

- Patients must have =< grade 2 pre-existing peripheral neuropathy (per Common
Terminology Criteria for Adverse Events [CTCAE] v4.0)

- Ability to complete questionnaire(s), in English, by themselves or with assistance

- Provide informed written consent

- Willing to provide blood samples for correlative research purposes

Exclusion Criteria:

- Radiographic evidence measurable of residual or metastatic disease after surgery

- Any of the following because this study involves an agent that has known genotoxic,
mutagenic and teratogenic effects to a developing fetus or nursing child:

- Pregnant women

- Nursing women

- Men or women of childbearing potential who are unwilling to employ adequate
contraception

- Co-morbid systemic illnesses or other severe concurrent disease which, in the
judgment of the investigator, would make the patient inappropriate for entry into
this study or interfere significantly with the proper assessment of safety and
toxicity of the prescribed regimens

- Immunocompromised patients and patients known to be human immunodeficiency virus
(HIV) positive and currently receiving antiretroviral therapy; NOTE: Patients known
to be HIV positive, but without clinical evidence of an immunocompromised state, are
eligible for this trial

- Uncontrolled intercurrent illness including, but not limited to, ongoing or active
infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
arrhythmia, or psychiatric illness/social situations that would limit compliance with
study requirements

- Receiving any other investigational agent which would be considered as a treatment
for the primary neoplasm

- Other active malignancy =< 3 years prior to registration except for locally curable
cancers that have been in apparently cured, such as basal or squamous cell skin
cancer, prostate cancer without evidence of prostate-specific antigen (PSA)
progression or carcinoma in situ such as the following: gastric, cervix, colon,
melanoma or breast for example

- History of myocardial infarction =< 6 months, or congestive heart failure requiring
use of ongoing maintenance therapy for life-threatening ventricular arrhythmias

- Pure small cell histologic variant or other pure non-urothelial carcinomas